Desferrioxamine-related ocular toxicity: A case report

被引:25
作者
Simon, Sumu [1 ]
Athanasiov, Paul A. [1 ]
Jain, Rajeev [1 ]
Raymond, Grant [1 ]
Gilhotra, Jagjit S. [1 ]
机构
[1] Royal Adelaide Hosp, Dept Ophthalmol & Visual Sci, Retinal Unit, Adelaide, SA 5000, Australia
关键词
Desferrioxamine; ocular toxicity; optic neuropathy; pigmentary retinopathy; DEFEROXAMINE INFUSION; RETINOPATHY; THALASSEMIA; THERAPY;
D O I
10.4103/0301-4738.98714
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
A 29-year-old lady receiving repeated blood transfusions for beta thalassemia since childhood, presented with rapidly deteriorating symptoms of night blindness and peripheral visual field loss. She was recently commenced on high-dose intravenous desferrioxamine for reducing the systemic iron overload. Clinical and investigative findings were consistent with desferrioxamine-related pigmentary retinopathy and optic neuropathy. Recovery was partial following cessation of desferrioxamine. This report highlights the ocular side-effects of desferrioxamine mesylate and the need to be vigilant in patients on high doses of desferrioxamine.
引用
收藏
页码:315 / U165
页数:3
相关论文
共 9 条
[1]  
[Anonymous], THALASSAMIA SYNDROME
[2]   Desferrioxamine related maculopathy: A case report [J].
Arora, A ;
Wren, S ;
Evans, KG .
AMERICAN JOURNAL OF HEMATOLOGY, 2004, 76 (04) :386-388
[3]  
DAVIES SC, 1983, LANCET, V2, P181
[4]   Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemia [J].
Davis, BA ;
Porter, JB .
BLOOD, 2000, 95 (04) :1229-1236
[5]   The expanded clinical spectrum of deferoxamine retinopathy [J].
Haimovici, R ;
D'Amico, DJ ;
Gragoudas, ES ;
Sokol, S .
OPHTHALMOLOGY, 2002, 109 (01) :164-171
[6]   Rapid development of severe toxic retinopathy associated with continuous intravenous deferoxamine infusion [J].
Lai, TYY ;
Lee, GKY ;
Chan, WM ;
Lam, DSC .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2006, 90 (02) :243-244
[7]   Iron-chelating therapy and the treatment of thalassemia [J].
Olivieri, NF ;
Brittenham, GM .
BLOOD, 1997, 89 (03) :739-761
[8]   DESFERRIOXAMINE OTOTOXICITY - EVALUATION OF RISK-FACTORS IN THALASSEMIC PATIENTS AND GUIDELINES FOR SAFE DOSAGE [J].
PORTER, JB ;
JASWON, MS ;
HUEHNS, ER ;
EAST, CA ;
HAZELL, JWP .
BRITISH JOURNAL OF HAEMATOLOGY, 1989, 73 (03) :403-409
[9]   A risk benefit assessment of iron-chelation therapy [J].
Porter, JB .
DRUG SAFETY, 1997, 17 (06) :407-421